As a part of our philosophy to build sustainable and scalable business model, Ajanta Pharma set its eye on entering the world's largest and most stringent pharmaceutical market - USA. We carved out select product portfolio, which include complex technology products to get the competitive advantage in the market place. We have also made substantial investments in our R&D facilities and thereby acquired required technical and regulatory expertise to penetrate the market.
In our quest for expansion in the regulated markets, we expect US market to be our key growth driver in the coming years. With an objective of building a critical size in the marketplace, many important programs are on the cards like investments in R&D, Manufacturing, Team, etc. Our products are already available on the shelf in US through our subsidiary, located in New Jersey, the hub of pharma industry in USA.
Currently we have 27 final approved products by US Food and Drug Administration (FDA), which are either commercialized or in process of being commercialized. Additional 2 ANDAs is tentatively approved, and other 21 ANDAs are under review with the US FDA (as on 31st March 2019). We are further planning to file about 10-12 ANDA's every year.